JANX vs XYL · rev $10.3M vs P/E 27, rev $4.46B
Janux Therapeutics Inc (JANX) versus Xylem Inc (XYL) — a side-by-side from cached financials, not a winner call.
Janux Therapeutics Inc (JANX) is a biotechnology company listed on US.
Xylem Inc (XYL) is a specialty industrial machinery company listed on NYSE.
Latest reported JANX revenue for 2026-06-30 was $10.3M. Net income was -$22.0M. JANX currently screens at market cap $1.49B.
Latest reported XYL revenue for 2026-06-30 was $4.46B. Net income was $456.0M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
JANX currently screens at market cap $1.49B. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
Not investment advice. Open the JANX and XYL stock pages for the full models.
Not investment advice.